1351234-12-2 Usage
General Description
The chemical 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2,2,2-trifluoroethoxy)pyrimidine, also known as TMDP, is a pyrimidine-based compound with boron and trifluoroethoxy functional groups. This chemical is used in the field of organic synthesis and medicinal chemistry for various applications, including as a reagent for cross-coupling reactions and as a building block for the synthesis of pharmaceutical compounds. TMDP is known for its stability and compatibility with a wide range of reaction conditions, making it a valuable tool for the synthesis of complex organic molecules. The boron and trifluoroethoxy groups in TMDP also contribute to its unique reactivity and selectivity in chemical reactions, making it a versatile and valuable compound in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1351234-12-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,1,2,3 and 4 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1351234-12:
(9*1)+(8*3)+(7*5)+(6*1)+(5*2)+(4*3)+(3*4)+(2*1)+(1*2)=112
112 % 10 = 2
So 1351234-12-2 is a valid CAS Registry Number.
1351234-12-2Relevant articles and documents
SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES
-
Paragraph 0223, (2021/11/20)
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.
PYRIDAZINONE COMPOUNDS AND USES THEREOF
-
Paragraph 215, (2020/06/01)
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.
